$42.44
0.06 (+0.14%)
GlaxoSmithKline plc (ADR) (GSK)
CAPS Rating:
The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products.
RSS Headlines
Fool UK
Recs
Glaxo Smith Kline is a diversified multinational drug maker with a long and profitable history. They recently acquired a favorite of mine, Sirtris Pharmaceuticals. Sirtris is pursuing research into anti-aging properties of the Sirtuin genes which are activated by Resveratrol, a component found in red wine.
Given the the broad applicability of the Sirtuin activators this represents a very interesting opportunity. Of course GSK is much more than Sirtris. They have a diversified portfolio of drugs and a global base. Another interesting avenue they are pursuing includes a collaboration with Exelixis Pharma on MET inhibitor XL880. GSK has the right to select a second Exelixis compound for further development this fall.
By all accounts GSK is well run and likely to outperform over the coming five years. Buy now while the market is beaten down.
Smart to follow the Sirtris money - there will be mult therapeutic avenues as the clinical data accumulates.